Serum uric acid and multiple sclerosis

Clinical Neurology and Neurosurgery

Volumn 108, Issue 6, 2006, Pages 527-531

  Rentzos, M ^a   Nikolaou, C ^a   Anagnostouli, M ^a   Rombos, A ^a   Tsakanikas, K ^a   Economou, M ^a   Dimitrakopoulos, A ^a   Karouli, M ^a   Vassilopoulos, D ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Multiple sclerosis; Neuroprotection; Treatment; Uric acid

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; NITRIC OXIDE; URIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE DURATION; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL DISABILITY; SCORING SYSTEM; SEX RATIO; URIC ACID BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; CASE-CONTROL STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; SEVERITY OF ILLNESS INDEX; URIC ACID;

EID: 33747058018     PISSN: 03038467     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clineuro.2005.08.004     Document Type: Article

References (31)

1. Bagasra O., Michaels F.H., Zheng Y.M., et al. Activation of the inducible form of nitric oxide synthase in the brain of the patients with multiple sclerosis. Proc Natl Acad Sci USA 92 (1995) 12041-12045
2. Cross A.H., Manning P.T., Keeling R.M., Schmidt R.H., and Misko T.P. Peroxynitrite formation within the central nervous system in active multiple sclerosis. J Neuroimmunol 88 (1998) 45-56
3. Mousavizadech K., Dehpour A.R., Minagar A., and Ghafourifar A. Uric acid: a novel treatment strategy for multiple sclerosis. Trends Pharmacol Sci 24 (2003) 563-564
4. Traugott U., Reinherz E., and Raine C.S. Multiple sclerosis. Distribution of T cells subsets and Ia-positive macrophages in lesions of different ages. J Neuroimmunol 4 (1983) 201-221
5. Toncev G., Milicic B., Toncev S., and Samardzic G. Serum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunction. Eur J Neurol 9 (2002) 221-226
6. Mattle H.P., Lienert C., and Greeve I. Uric acid and multiple sclerosis. Ther Umsch 61 (2004) 553-555
7. Hooper D.C., Bagasra O., Marini J.C., et al. Prevention of experimental allergic encephalo-myelitis by targeting nitric oxide and peroxynitrite: implications for the treatment of multiple sclerosis. Proc Natl Acad Sci USA 94 (1997) 2528-2533
8. Hooper D.C., Spitsin S., Kean R.B., et al. Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalo-myelitis and multiple sclerosis. Proc Natl Acad Sci USA 95 (1998) 675-680
9. Sotgiu S., Pugliatti M., Sanna A., et al. Serum uric acid and multiple sclerosis. Neurol Sci 23 (2002) 183-188
10. Drulovic J., Dujmovic I., Stojsavljevic N., et al. Uric acid levels in sera from patients with multiple slerosis. J Neurol 248 (2001) 121-126
11. Toncev G., Milicic B., Toncev S., and Samardzic G. High-dose methylprednisolone therapy in multiple sclerosis increases serum uric acid levels. Clin Chem Lab Med 40 (2002) 505-508
12. Constantinescu C.S., Freitag P., and Kappos L. Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis. Mult Scler 6 (2000) 378-381
13. Miller A., Glass-Marmor L., Abraham M., Grossman I., Shapiro S., and Galboiz Y. Bio-markers of disease activity and response to therapy in multiple sclerosis. Clin Neurol Neurosurg 106 (2004) 249-254
14. McDonald W.I., Compston A., Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50 (2001) 121-127
15. Jacobs L.D., Beck R.W., Simon J.H., et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 357 (2000) 898-904
16. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33 (1983) 1444-1452
17. Radi R., Beckman J.S., Bush K.M., and Freeman B.A. Peroxynitrite-induced membrane lipid peroxydation: the cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys 288 (1991) 481-487
18. Vladimirova O., O'Connor J., Cahill A., Alder H., Butunoi C., and Kalman B. Oxidative damage to DNA in plaques of MS brains. Mult Scler 4 (1998) 413-418
19. Whiteman M., and Halliwell B. Protection against peroxynitrite-dependent tyrosine nitration and alpha 1-proteinase inactivation by ascorbic acid. A comparison with other antioxidants. Free Radic Res 25 (1996) 275-283
20. Ischiropoulos H., Zhu L., Chen J., et al. Peroxynitrite-mediated tyrosinase nitration catalyzed by superoxide dismutase. Arch Biochem Biophys 298 (1992) 431-437
21. Hooper D.C., Ohnishi S.T., Kean R., Numagami Y., Dietzschold B., and Koprowski H. Local nitric oxide production in viral and autoimmune diseases of the central nervous system. Proc Natl Acad Sci USA 92 (1995) 5312-5316
22. Brundin L., Morcos E., Olsson T., Wiklund N.P., and Andersson M. Increased intrathecal nitric oxide formation in multiple sclerosis; cerebrospinal fluid nitrite as activity marker. Eur J Neurol 6 (1999) 585-590
23. -) levels in cerebrospinal fluid of patients with multiple sclerosis. J Neurol Sci 153 (1997) 32-34
24. Hooper D.C., Scott G.S., Zborek A., et al. Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood-CNS barrier permeability changes, and tissue damage in a mouse model of multiple sclerosis. FASEB J 14 (2000) 691-698
25. Knapp C.M., Constantinescu C.S., Tan J.H., McLean R., Cherryman G.R., and Gottlob I. Serum uric acid levels in optic neuritis. Mult Scler 10 (2004) 278-280
26. Thompson A.J., Polman C.H., Miller D.H., et al. Primary progressive multiple sclerosis. Brain 120 (1997) 1085-1096
27. Michalopoulou M., Nikolaou C., Tavernarakis A., Alexandri N.M., Rentzos M., Chatzipanagiotou S., et al. Soluble interleukin-6 receptor (sIL-6R) in cerebrospinal fluid of patients with inflammatory and non inflammatory neurological diseases. Immunol Lett 94 (2004) 183-189
28. Lorsbach R.B., Murphy W.J., Lowenstein C.J., Snyder S.H., and Russell S.W. Expression of the nitric-oxide synthase gene in mouse macrophages activated for tumor cell killing. Molecular basis for the synergy between interferon-γ and lipopolysaccharide. J Biol Chem 268 (1993) 1908-1913
29. Hua L.L., Liu J.S., Brosnan C.F., and Lee S.C. Selective inhibition of human glial inducible nitric oxide synthase by interferon-beta: implication for multiple sclerosis. Ann Neurol 43 (1998) 384-387
30. Spitsin S., Hooper D.C., Leist T., Streletz L.J., Mikheeva T., and Koprowski H. Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease. Mult Scler 7 (2001) 313-319
31. Spitsin S., Hooper D.C., Mikheeva T., and Koprowski H. Uric acid levels in patients with multiple sclerosis: analysis in mono-and dizygotic twins. Mult Scler 7 (2001) 165-166